Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Newron Pharmaceuticals SpA ( (CH:NWRN) ).
Newron Pharmaceuticals has initiated the Phase III ENIGMA-TRS program to evaluate Evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS). This international study will involve at least 600 patients and aims to provide a new treatment option for those who do not respond adequately to current antipsychotics. The study’s 12-week results are expected in Q4 2026, and it builds on previous findings that demonstrated Evenamide’s efficacy and favorable safety profile. The program’s success could significantly impact Newron’s market positioning and offer a breakthrough for TRS patients.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on developing novel therapies for central and peripheral nervous system disorders. Based in Bresso, near Milan, Italy, the company is known for its lead drug candidate, Evenamide, a first-in-class glutamate modulator aimed at treating treatment-resistant schizophrenia (TRS) and patients who do not respond adequately to current therapies. Newron has a history of successful CNS therapy development, including the Parkinson’s drug Xadago® (Safinamide), which is approved in over 20 markets globally.
Average Trading Volume: 35,375
Technical Sentiment Signal: Buy
Current Market Cap: CHF149.1M
See more data about NWRN stock on TipRanks’ Stock Analysis page.